Overview

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can improve (decrease) blood glucose values in Asian patients with Type 2 Diabetes who have never been treated with medication or have been on medication for less than 24 weeks since their original diagnosis of Diabetes. The safety of this treatment will also be studied.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

AstraZeneca, Bristol-Myers Squibb

Treatments:

Dapagliflozin
Metformin